Results 91 to 100 of about 618,162 (164)

Histiocytes: Multifaceted Regulators of Health and Disease

Veterinary Clinical Pathology, EarlyView.
ABSTRACT The mononuclear phagocyte system encompasses macrophages, dendritic cells (DCs), and monocytes. Tissue‐resident macrophages and dendritic cells arise during embryogenesis and are replenished either through self‐renewal or by monocytes during inflammation.
Erika J. Gruber
wiley   +1 more source

Challenges in the Discovery of Indoleamine 2,3-Dioxygenase 1 (IDO1) Inhibitors

Since the discovery of indoleamine 2,3-dioxygenase 1 (IDO1) as an attractive target for anticancer therapy in 2003, the search for inhibitors has been intensely pursued both in academia and in pharmaceutical companies. Many novel IDO1 inhibitor scaffolds
Roehrig, Ute F., Michiein, Olivier, Zoete, Vincent, Majjigapu, Somi Reddy, Vogel, Pierre   +4 more
core   +1 more source

Translating gut microbiome research into therapies for type 1 diabetes

Experimental Physiology, EarlyView.
Abstract Type 1 diabetes (T1D) is characterised by the loss of functional pancreatic β‐cells, for which lifelong insulin therapy remains the standard of care. Given that the gut microbiome can influence host health and that shifts in gut microbial profiles have been observed in T1D, growing interest has emerged in the role of the gut microbiome in T1D,
Shanti P. Kok, Max Nieuwdorp, Elena Rampanelli   +2 more
wiley   +1 more source

Binding properties of different categories of IDO1 inhibitors: a microscale thermophoresis study

, 2017
Aim: Inhibition of IDO1 is a strategy pursued in the immune-oncology pipeline for the development of novel anticancer therapies. At odds with an ever-increasing number of inhibitors being disclosed in the literature and patent applications, only very ...
Nina Schlinck, Daniela Dolciami, Coletti, Alice, Antonio Macchiarulo, Chiara Custodi, Custodi, Chiara, Carotti, Andrea, Marinozzi, Maura, Andrea Carotti, Dolciami, Daniela, Schlinck, Nina, Macchiarulo, Antonio, Francesco Antonio Greco, Alessandro Di Michele, Maura Marinozzi, Di Michele, Alessandro, Alice Coletti, Greco, Francesco Antonio   +17 more
core   +1 more source

Tumor‐Regional Immune Microenvironment: A Critical Factor in the Design of Radiotherapy–Immunotherapy Combination Trials

International Journal of Cancer, Volume 159, Issue 8, Page 1857-1872, 15 October 2026.
ABSTRACT Clinical trials combining radiotherapy (RT) with immune checkpoint blockade (ICB) have shown improved outcomes in only a fraction of patients, and optimal strategies for integrating these modalities remain under intense investigation. With a few exceptions, phase III combination trials have yielded disappointing results.
Xuanwei Zhang, Hui Wang, Weiyan Tang, Kai Kang, Kateryna Onyshchenko, Taotao Huang, Dan Liu, Jianxin Xue, You Lu, Gabriele Niedermann, Ren Luo   +10 more
wiley   +1 more source

Design, synthesis and biological evaluation of erlotinib-based IDO1 inhibitors. [PDF]

Front Pharmacol, 2022
Hou XX, Gong XQ, Mao LF, Sun G, Yang JX.
europepmc   +1 more source

Microbiome‐Derived Tryptophan Metabolites Regulate AhR Signaling to Restore Epithelial Barrier Integrity in Inflammatory Bowel Disease

MicrobiologyOpen, Volume 15, Issue 5, October 2026.
The graphical abstract illustrates how microbiome‐derived indoles activate the aryl hydrocarbon receptor to restore the intestinal barrier. The picture contrasts the “leaky gut” state with the restored homeostasis achieved through AMPK, Nrf2, and IL‐22 signaling.
Mohammad Ali Mahdiabadi, Asma Moghaddam, Nafiseh Erfanian   +2 more
wiley   +1 more source

Abstract 5581: Development of 2nd generation indoleamine 2,3-dioxygenase 1 (IDO1) selective inhibitors

, 2017
Harnessing the immune system via immune checkpoint blockade (e.g. anti PD-1, anti PD-L1, anti CTLA4) has led to fast and long lived responses in cancer patients.
James Kelly, Simon Armitage, Richard Armer, Sheenagh Aiken, Abhijith Thippeswamy, Lucy Cartwright, Catherine Eagle, Thomas Pesnot, Caroline Phillips, Philip MacFaul, John Maclean, Sachin Mahale, Aleksandr Grisin, Matilda Bingham   +13 more
core   +1 more source

Structure–activity relationship studies of 5-(Pyridin-3-yl)-1H-indole-4,7-diones as indoleamine 2,3-dioxygenase 1 inhibitors

Results in Chemistry
Indoleamine 2,3-dioxygenase 1 (IDO1) is the key enzyme that catalyzes the conversion of l-tryptophan (Trp) to N-formyl-kynurenine in the tryptophan-kynurenine (Trp-Kyn) pathway.
Jiawei Zhang, Jingyi Liu, Kaimin Kong, Xingzhou Li, Qian Zhang   +4 more
doaj   +1 more source

Ineffectiveness of immune checkpoint inhibitors in prostate cancer: is it just a question of ‘‐mabs’?

The Journal of Pathology, Volume 270, Issue 2, Page 139-162, October 2026.
Abstract Prostate cancer (PCa) is the second most common type of neoplasm, currently treated with a variety of therapeutic agents. Although advances in treatment over the past decade have improved overall survival, patients with advanced PCa eventually progress from hormone‐sensitive PCa to metastatic castration‐resistant PCa.
Giuseppe Schepisi, Irene Torresan, Emilio Francesco Giunta, Sara Bleve, Nicole Brighi, Elisa Tassinari, Sofia Zanuccoli, Maria Concetta Cursano, Cristian Lolli   +8 more
wiley   +1 more source